Optimizing cell culture media and process designs for increased titers, quality, and manufacturability is an important part of the development process of biological drugs. In a traditional media development workflow, spent media analyses of fewer than 50 molecules, including selected water-soluble vitamins and amino acids, are used in iterative steps to optimize media formulations.
With the power of proteomics and metabolomics to multiply media characterization intelligence and improve productivity, the new multi-omics workflow combines spent media and cellular component analyses of up to 8,000 molecules—including 7,000 proteins and 1,000 metabolites. This workflow relies on best-in-class technology to support data intelligence, which includes the highest resolution UPLC-MS instrumentation and the use of predictive modeling and bioinformatics, and to obtain the deeper metabolic insights needed to create more precise media and feeds that unlock the productivity potential of cell lines.
In today’s Knowledge Culture Basics Education Series on multi-omics and bioinformatics in cell culture media design, we will explain about the evolution of medium design for cell culture bioprocessing, multi-omics in medium design, how proteomics and metabolomics are utilized for media development, and a case study using multi-omics media development workflow.
Learning Objectives
- The evolution of medium design for cell culture bioprocessing
- Multi-omics in medium design
- How proteomics and metabolomics are utilized for cell culture media development
- Case study
Speakers
Paul Gulde
Multi-Omics Team, BioProduction Group R&D, Thermo Fisher Scientific
Paul Gulde is a manager of BioProduction Group R&D and graduated from the University at Buffalo with Ph.D. in Microbiology and Immunology. He joined Thermo Fisher Scientific in 2009. He has 12 years of experience in cell culture medium development for both custom and catalog formulations. He now leads a multi-omics R&D team. His team is investigating the use of proteomics and metabolomics to advance upstream bioprocesses for the production of therapeutic proteins and vaccines.
Chengjian Tu
Multi-Omics Team, BioProduction Group R&D, Thermo Fisher Scientific
Chengjian Tu is a staff scientist of BioProduction Group R&D and received his Ph.D. from Shanghai Institute of Biochemistry and Cell Biology in Biochemistry and Cell Biology. He has been in the field of mass spectrometry-based omics for more than 15 years. He joined Thermo Fisher Scientific in 2018. Since then, he has established and applied the multi-omics platform to advance cell culture medium development for CHO, HEK, and T-cells, etc.